Search Result

Results for "

CDK2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (278) AAK1 (1) Akt (8) AMPK (3) Anaplastic lymphoma kinase (ALK) (2) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (85) ATM/ATR (1) Aurora Kinase (5) Autophagy (11) Bacterial (1) Bcl-2 Family (10) c-Kit (1) c-Myc (3) Calcium Channel (1) CaMK (1) Carbonic Anhydrase (6) Casein Kinase (1) Caspase (10) CFTR (1) Checkpoint Kinase (Chk) (2) Cholinesterase (ChE) (2) COX (1) CXCR (3) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (4) Drug Intermediate (1) Drug Isomer (1) E1/E2/E3 Enzyme (1) EGFR (15) Endogenous Metabolite (1) Enterovirus (1) Epigenetic Reader Domain (1) ERK (2) FAK (1) FGFR (1) FLT3 (6) GSK-3 (24) HDAC (2) Heme Oxygenase (HO) (3) HIV (3) HSP (2) IAP (1) IKK (1) Interleukin Related (4) Isotope-Labeled Compounds (3) JAK (6) JNK (4) Keap1-Nrf2 (4) Ligands for Target Protein for PROTAC (3) LIM Kinase (LIMK) (1) MAP4K (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (4) MEK (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) MMP (1) Molecular Glues (7) mTOR (4) MyD88 (2) Necroptosis (2) NEKs (2) NF-κB (2) P-glycoprotein (1) p38 MAPK (3) Parasite (2) PARP (3) PDGFR (1) PERK (1) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (7) Pim (4) PKA (1) PKC (9) PKD (2) PROTACs (7) Ras (1) Reactive Oxygen Species (ROS) (7) Reference Standards (25) Reverse Transcriptase (1) RIO Kinase (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (1) Ser/Thr Kinase (3) Sirtuin (1) SnRK (1) SphK (1) Src (4) STAT (4) Survivin (2) Telomerase (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (2) Trk Receptor (2) VEGFR (12) Wee1 (3)
By Research Areas:	Cancer (275) Cardiovascular Disease (4) Infection (9) Inflammation/Immunology (27) Metabolic Disease (8) Neurological Disease (29)
Click Chemistry:	Alkynes (1)

308

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162001

INX-315 5+ Cited Publications	CDK	Cancer
INX-315 is an orally active and selective *CDK2* inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces *CDK2* substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research .

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and *CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A* and aurora-B, respectively .

HY-15339

CVT-313 5+ Cited Publications CDK2 Inhibitor III	CDK	Cancer
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of *CDK2* with IC₅₀ of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .

HY-130709

PROTAC CDK2/9 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for *CDK2* (DC₅₀=62 nM) and CDK9 (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .

HY-18299A

Purvalanol A 4 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent CDK1 and *CDK2* inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for CDK1/cyclinB and *CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2* over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) .

HY-164664

CDK2-IN-30	CDK	Cancer
CDK2-IN-30 is a *CDK2* inhibitor with an IC₅₀ value ≤20 nM. CDK2-IN-30 modulates CDK2 activity to influence cell cycle regulation. CDK2-IN-30 can be used for the research of cancer .

HY-117535

CDK2-IN-4 3 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-15004

AUZ 454 5+ Cited Publications K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-148214

CDK2/4/6-IN-2	CDK	Cancer
CDK2/4/6-IN-2 is a selective *CDK2/4/6* inhibitor with IC₅₀ values <1 μM. CDK2/4/6-IN-2 inhibits cells proliferation and phosphorylation of retinoblastoma protein at Ser807/811 in breast cancer cells. CDK2/4/6-IN-2 can be used for the research of cancer, such as breast cancer .

HY-N6953

Garcinone D 4 Publications Verification	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)	Neurological Disease
Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and *CDK2* inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively .

HY-159805

CDK2-IN-31	CDK	Cancer
CDK2-IN-31 is a *CCNE1:CDK2* complex inhibitor with an IC₅₀ of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer .

HY-112460

CDK2-IN-3	CDK	Cancer
CDK2-IN-3 (compound 3) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 60 nM .

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-100600

BGG463 K03859	CDK	Others
BGG463 (K03859) is an orally active type II *CDK2* inhibitor .

HY-15166B

(E/Z)-Zotiraciclib citrate 5+ Cited Publications (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent *CDK2, JAK2, and FLT3* inhibitor .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, *CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-163357

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-157516

CDK2-IN-22	CDK	Cancer
CDK2-IN-22 (compound 7I) is a potent *CDK2* inhibitor with an IC₅₀ of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC₅₀ values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .

HY-170897

CDK2-IN-40	CDK	Cancer
CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits *CDK2*/Cyclin E1 with an IC₅₀ of ≤ 10 nM .

HY-W478102

CDK2-IN-13	CDK	Cancer
CDK2-IN-13 (Compound 15) is a *CDK2* inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .

HY-120497

PKCζ-IN-1	PKC CDK	Cancer
PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.

HY-112468

PNU112455A hydrochloride	CDK	Cancer
PNU112455A hydrochloride is an ATP-competitive *CDK2* and CDK5 inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively .

HY-103646

CK7	NEKs CDK	Others
CK7, a *Cdk2/9* inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-123045

PNU-292137	CDK	Cancer
PNU-292137 is an orally active, potent *CDK2* inhibitor with IC₅₀s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134622

GSK-3/CDK5/CDK2-IN-1	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, *cdk2, and GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-151580S

CDK2-IN-14-d3	CDK	Cancer
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-151573

EGFR/CDK2-IN-1	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-111356

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral CDK inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-178112

CDK2-IN-47	CDK Apoptosis	Cancer
CDK2-IN-47 is a potent *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer .

HY-178756

CDK2-IN-48	CDK	Cancer
CDK2-IN-48 (Compound 109) is a *CDK2* inhibitor with IC₅₀ values for *CDK2* and CDK1 of respectively < 0.05 and > 1 μM. CDK2-IN-48 can be used for the study of CDK2-dependent cancers .

HY-151580

CDK2-IN-14	CDK	Cancer
CDK2-IN-14 (compound 4f) is a highly selective *CDK2* inhibitor. CDK2-IN-14 can be used in research of cancer .

HY-168057

PROTAC CDK2 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-169048

CDK2/4-IN-2	CDK	Cancer
CDK2/4-IN-2 (compound 56) is a *CDK2* and CDK4 dual inhibitor with IC₅₀s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .

HY-173124

CDK2/FLT4/PDGFRA-IN-1	CDK VEGFR PDGFR Apoptosis	Cancer
CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC₅₀s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .

HY-148651

CDK2-IN-15	CDK	Cardiovascular Disease Cancer
CDK2-IN-15 (Compound 19) is an inhibitor of *CDK2* with an IC₅₀ of 2.9 μM. CDK2-IN-15 can be used for cancer research .

HY-155441

CDK2-IN-20	CDK	Cancer
CDK2-IN-20 (compound 3b) is an inhibitor of *CDK2. CDK2-IN-20* has cytotoxicity on tumor cells presenting an IC₅₀ range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .

HY-162270

CDK2-IN-24	CDK	Cancer
CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-W478102S

CDK2-IN-13-d3	Isotope-Labeled Compounds CDK	Cancer
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-169683

CDK2-IN-39	CDK	Cancer
CDK2-IN-39 (compound 4) is a *CDK2* inhibitor .

HY-139651

CDK2-IN-7	CDK	Cancer
CDK2-IN-7 is a *CDK2* inhibitor for researching cancer (IC₅₀ < 50 nM).

HY-144811

CDK2-IN-9	CDK Apoptosis	Cancer
CDK2-IN-9 is a potent *CDK2* inhibitor with an IC₅₀ of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .

HY-179161

CDK2-IN-49	CDK MDM-2/p53 Bcl-2 Family Apoptosis	Cancer
CDK2-IN-49 (Compound 5j) is a *CDK2* inhibitor with an IC₅₀ of 0.25 μM. CDK2-IN-49 shows potent activity against CDK7 with an IC₅₀ of 0.14 μM. CDK2-IN-49 induces Apoptosis by raising the levels of p53 and Bax protein expression while reducing the amount of Bcl-2. CDK2-IN-49 inhibits cell division. CDK2-IN-49 can be used in the research of cancer .

Cat. No.	Product Name	Type

HY-B1817A

Zinc acetate, 99.99% trace metals basis

Zinc(II) acetate, 99.99% trace metals basis

Biochemical Assay Reagents

Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions .

HY-W002616

5-Bromoindolin-2-one 5-Bromooxindole	Biochemical Assay Reagents
5-Bromoindolin-2-one (5-Bromooxindole) is a synthetic intermediate. 5-Bromoindolin-2-one can be used for the synthesis of CDK2 inhibitors and antibacterial agents .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18981

Decursin 2 Publications Verification (+)-Decursin	Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC. Source Classification	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-N0260

Epmedin C Maximum Cited Publications 6 Publications Verification Epimedin-C; Baohuoside-VI	Flavonols Structural Classification Monophenols Flavonoids Classification of Application Fields Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Inflammation/Immunology Disease Research Fields Source Classification	Keap1-Nrf2 CDK Caspase
Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of *CDK2/Cyclin* E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia .

HY-N5072

Desmethylglycitein 3 Publications Verification 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Disease Research Fields Isoflavones Source Classification Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Structural Classification Polysaccharides Animals Classification of Application Fields Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

HY-N6953

Garcinone D 4 Publications Verification	Xanthones Guttiferae Phenols Polyphenols Garcinia mangostana Linn. Plants Source Classification	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-119979

Cardanol monoene Cardanol C15:1	Monophenols Classification of Application Fields Phenols Plants Anacardium occidentaleL. Disease Research Fields Anacardiaceae Source Classification Cancer	Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism MMP CDK Caspase Bcl-2 Family PARP MDM-2/p53 Cholinesterase (ChE)
Cardanol monoene (Cardanol C15:1) is a phenolic compound which can be found in cashew nut shell liquid. Cardanol monoene can inhibit cancer cells proliferation, migration, cause S phase arrest, induce apoptosis, ROS production and mitochondrial depolarization. Cardanol monoene downregulates MMP-2, MMP-9, cyclinA1 expression, regulates *CDK2, p53, Bax, cytochrome c, cleaved caspase-3, cleaved PARP, Apaf-1* expression and Bax/Bcl-2 ratio. Cardanol monoene shows weak DPPH radical scavenging activity and AChE inhibition activity. Cardanol monoene is lethal to Artemia salina nauplii. Cardanol monoene. Cardanol monoene can be used for the research of cancer, infection and inflamation .

HY-N1465

Aristolochic acid D Aristolochic acid-IVa	Structural Classification Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Phenols Plants Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) CDK Interleukin Related
Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC₅₀: 4.673 μM) and *CDK2* (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .

HY-N3389

Licoisoflavone A 2 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the *CDK2-Cyclin* E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-W097625

6-Methoxyflavone	Flavonoids Flavones Thymelaeaceae Plants Pimelea simplex F.Muell. Source Classification	Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO)
6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the *CCNA2/CDK2/p21CIP*1 signaling pathway in HeLa cells. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .

HY-N8146

Bruceantinol	Infection Triterpenes Simaroubaceae Classification of Application Fields Brucea antidysenterica J.F.Mill. Terpenoids Plants Disease Research Fields Brucea javanica (L.) Merr. Source Classification Cancer	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with *CDK2/4/6* to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .

HY-N5072R

Desmethylglycitein (Standard) 4',6,7-Trihydroxyisoflavone (Standard)	Structural Classification Flavonoids Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Isoflavones Source Classification	Reference Standards CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-149436

CDK2/Bcl2-IN-1	Terpenoids Zygophyllaceae Diterpenoids Plants Zygophyllum album L.f. Source Classification	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-N6953R

Garcinone D (Standard)	Structural Classification Xanthones Guttiferae Phenols Polyphenols Garcinia mangostana Linn. Plants Source Classification	Reference Standards STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D (Standard) is the analytical standard of Garcinone D (HY-N6953). This product is intended for research and analytical applications. Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-N0260R

Epmedin C (Standard) Epimedin-C (Standard); Baohuoside-VI (Standard)	Flavonols Structural Classification Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Source Classification	Reference Standards Keap1-Nrf2 CDK Caspase
Epmedin C (Standard) is the analytical standard of Epmedin C. This product is intended for research and analytical applications. Epmedin C (Epimedin-C; Baohuoside-VI) is an orally active anti-inflammatory agent and immunomodulator that binds to multiple key proteins including UCP1, Caspase-1, CDK2 and Keap1. Epmedin C inhibits epithelial cell proliferation by disrupting the complex function of *CDK2/Cyclin* E. Epmedin C also upregulates Nrf2 expression, reduces ROS levels and inhibits pro-inflammatory cytokine secretion, thereby effectively restoring antibody production and alleviating tissue damage. Epmedin C has good safety with no hepatotoxicity or skin sensitization, and it has been used in studies on diseases such as obesity, Deoxynivalenol (HY-N6684)-induced immunotoxicity and mammary hyperplasia .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

HY-N1465R

Aristolochic acid D (Standard) Aristolochic acid-IVa (Standard)	Monophenols other families Ketones, Aldehydes, Acids Phenols Plants Source Classification	Reference Standards CDK Phosphodiesterase (PDE) Interleukin Related
Aristolochic acid D (Standard) (Aristolochic acid-IVa (Standard)) is the analytical standard of Aristolochic acid D (HY-N1465). This product is intended for research and analytical applications. Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC₅₀: 4.673 μM) and *CDK2* (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .

HY-W097625R

6-Methoxyflavone (Standard)	Structural Classification Flavonoids Flavones Thymelaeaceae Plants Pimelea simplex F.Muell. Source Classification	Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Reference Standards PERK
6-Methoxyflavone (Standard) is the analytical standard of 6-Methoxyflavone (HY-W097625). This product is intended for research and analytical applications. 6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway and activates the PERK/EIF2a/ATF4/CHOP pathway in HeLa cells. 6-Methoxyflavone acts as a Flumazenil (HY-B0009)-insensitive positive allosteric modulator at human recombinant α1β2γ2L and α2β2γ2L GABAα receptors. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .

Cat. No.	Product Name	Chemical Structure

HY-151580S

CDK2-IN-14-d3
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-W478102S

CDK2-IN-13-d3
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

HY-18981S

Decursin-d6

Decursin-d₆ ((+)-Decursin-d₆) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

Cat. No.	Product Name		Classification

HY-148213

CDK2/4/6-IN-1		Alkynes
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK2 Inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products